Personal tools
  • Log in    Register   
 

Agenda

 
Day One: Thursday 30th April 2009
| Day One | Day Two |
8.00
Registration and refreshments
8.50
Opening remarks from the Chair
Adam Gordois, Health Economics Manager, IMS Health Australia
POLICY REFORM
9.00
Addressing the effect of the current PBS model
  • Has the PBS reform had an impact? What are the issues that drive PBS reform and how do we measure outcomes?
  • What improvements could there be to the scheme design including sustainability of the PBS?
  • Do patients benefit from PBS reforms?
    • Generic substitution: what are the outcomes for patients?
    • How do we ensure equity of access through the PBS?
    • What is the effect of co-payments on prescription utilisation?
Shane Jackson, National Vice-President, Pharmaceutical Society of Australia
9.30
Examining policy reform and the impact of the changes
  • How effective are the changes to the PBS?
  • What will be the challenges?
  • How can industry address the changes?
  • What approach should government take in the future?
Peter Dutton MP, Shadow Minister for Health and Ageing
9.55
KEYNOTE ADDRESS Balancing government reform objectives, budget shortfalls, rising copayments, innovations in drug therapy and the rise of genomics
  • The health reform commission and the preventative health task force on healthcare financing: implications for the PBS
  • The threats to the PBS from world economic slowdown
  • Assessment of the flow-on effects of changes to the PBS
  • The new threats to PBS viability: copayments, primary care workforce, personalised medicine and genomics
  • The continuing barriers in access to essential medicines: shrinking R&D pipelines, generics takeup, Rx-to- OTC switches, regulatory reform and health literacy
  • The new tools: pharmacovigilance, linked datasets, an expanded primary care workforce, and better informed consumers
Paul Gross, Director, Institute of Health Economics and Technology Assessment
10.40
Morning tea
11.00
Identifying the impact of reform on the pharma industry
  • Are the reforms conducive to industry growth or do they stifle competition?
  • What impact do the PBS reforms have on industry innovation and investment?
  • How has the pharmaceutical industry addressed these challenges?
Ian Chalmers, Chief Executive, Medicines Australia
POLICY IMPLEMENTATION
11.30
Examining the effect of the PBS reforms on the public hospital pharmacy
  • Impact of reforms on the profitability for public hospitals
  • The effects of oncology milligram drug pricing on public hospitals
  • The future of the Highly Specialised Drugs Program
Michael Furey, Manager Blood & Pharmaceutical Programs, Department of Human Services Victoria
12.00
Practical aspects of supplying PBS pharmaceuticals to hospital patients
  • The issues surrounding PBS funding in public hospitals
  • The impact of changes to drug listings in the PBS
  • The implications for high cost drug distribution and utilisation
Chris Arthur, Director of Haematology, Royal North Shore Hospital
12.30
Lunch
BIOLOGICALS
1.30
Medical innovation, policy and PBS
  • Medical innovation and its place in the Australian policy agenda
  • The balance between short-term affordable access to medicines and market incentives for long-term innovation
  • The PBS and innovation: what it does well and what it doesn't
Angelika Maerz, Health Policy Manager, Wyeth Australia Pty Ltd
2.00
Examining the impact of pharmacogenomics on the PBS
  • Implications of the genomic revolution on the PBS
  • What steps are being taken to ensure access to new biologicals?
Ross McKinnon, Director, Sansom Institute, and Professor of Pharmaceutical Biotechnology in the School of Pharmacy and Medical Sciences, University of South Australia
2.30
Developing national framework for pharmacogenomics
  • Global trends in PGx uptake and government policies
  • Options for health technology assessment reform in Australia, future directions for the National Medicines Policy
  • Potential long run economic benefits for the community
Melanie Kelly, Director, Deloitte
3.00
Afternoon tea
CASE STUDY PALLIATIVE CARE AUSTRALIA
3.20
The PBS and small population groups – is our access to medicines equitable and effective?
  • The importance of equality of access in the PBS process
  • Making medicines accessible and affordable across Australia
  • The demands for medicines in remote areas
Donna Daniell, CEO, Palliative Care Australia
PANEL DISCUSSION
3.50
Reviewing PBS policy reform and its impact
Michael Furey, Manager Blood & Pharmaceutical Programs, Department of Human Services Victoria
Thomas Faunce, College of Law and Medical School, Australian National University
Melanie Kelly, Director, Deloitte
Ross McKinnon, Director, Sansom Institute, and Professor of Pharmaceutical Biotechnology in the School of Pharmacy and Medical Sciences, University of South Australia
4.40
Closing remarks from the Chair
4.50
End of day one
5.00
Networking drinks
 
Day Two: Friday 1st May 2009
| Day One | Day Two |
8.30
Coffee and networking
9.00
Opening remarks from the Chair
Sarah Matheson, Partner, Allens Arthur Robinson
MANUFACTURERS
9.10
Bringing new effective medicines to patients through continued investment in the innovative medicines industry
  • Has the reform increased price sensitivity and consumer willingness to pay for new inventions?
  • Do the reforms drain the level of investment for new products and innovation?
Alex Gosman, Director Government & Corporate Affairs, Glaxo SmithKline
9.40
Revealing the impact of the changes in the generic medicines industry and the implications for generics manufacturers
  • The impact of reform on the sustainability of the generics industry
  • The effect of reduced prices and volumes on generics
  • The role of key stakeholders in ensuring the generics industry delivers ongoing savings for government and consumers
  • Price disclosure – becoming reality
Gavin Upiter, Managing Director, Generic Health
10.10
The PBS – Stakeholder Perceptions and Public Relations
  • The evolution of PBS stakeholder perceptions
  • The PBS brand and public relations
  • The perceptions, PR and policy interface
  • International perspectives on the PBS
Tim James, Manager, Corporate and Government Affairs, Janssen-Cilag
10.40
Morning tea
WHOLESALERS
11.00
CSO and PBS Reforms: A Wholesaler's perspective
  • How has the reform changed the profitability of wholesalers?
  • Has the reforms changed the competitive landscape of distribution in Australia
  • What does the Fifth Government Guild Agreement have in store for wholesalers?
Brett Barons, National Manager Supply Chain, Symbion Pharmacy Services
11.30
Assessing the effectiveness of the CSO Funding Pool
  • Does the CSO Funding Pool improve the timely access of medicines across Australia?
  • Are there sufficient selection criteria to determine who has access to the CSO Funding Pool?
Saul Resnick, Director of Healthcare Australia, DHL Exel Supply Chain
CROSS INDUSTRY ROUND TABLE FORUM
12.00
Discussion and debate on the issues in PBS reform
  • Impact of reform on the generic and innovative industries
  • Implications of the changes for the pharma industry
Alex Gosman, Director Government & Corporate Affairs, Glaxo SmithKline
Gavin Upiter, Managing Director, Generic Health
Tim James, Manager, Corporate and Government Affairs, Janssen-Cilag
Brett Barons, National Manager Supply Chain, Symbion Pharmacy Services
Saul Resnick, Director of Healthcare Australia, DHL Exel Supply Chain
12.30
Lunch
LEGAL FACTORS
1.30
Legal issues surrounding the F1-F2 formularies
  • Do the F1-F2 changes increase the need for patent and IP protection?
  • Impact of F1-F2 changes on pharmaceutical marketing principles and PBS processes
  • Amendments to the F1-F2 changes?
  • Future of the F1-F2 formularies?
Thomas Faunce, College of Law and Medical School, Australian National University
2.00
Price disclosure, reporting and compliance - managing the legal obligations safely
  • What are the key legal issues and requirements to consider in the PBS listing process?
  • How should pharmaceutical companies handle price disclosure requirements and product information requests?
John Emmerig, Senior Partner, Blake Dawson
ECONOMIC FACTORS
2.30
Understanding the cost drivers of the PBS and the impact of PBS reforms
  • Likely outcomes of price reductions and price disclosure obligations on PBS spending
  • The impact of changes in copayments and safety net thresholds
  • Implications for access to medicines and sustainability
Kim Sweeney, Centre for Strategic Economic Studies, Victoria University
3.00
Afternoon tea
3.20
The growing role of local data collection to support decision making on PBS policy issues
  • Designing clinical studies that generate generalisable data
  • Evaluating the value of medicines in real world clinical practice
  • Analysing real world data to develop an optimal medicines policy
  • Post PBS listing observational data collection
Joyce Lloyd, Managing Director, Pretium Pty Ltd
3.50
The impact of the reforms on consumer demand and choice
  • Do the reforms go far enough in giving the consumer value for dollar paid in PBS fees to pharmacists?
  • Is there a more efficient way of providing PBS to consumers rather than the present "approved pharmacy" licensing system?
  • Is the consumer getting value for money in the cost of educating pharmacists in a four year degree course?
Rollo Manning, Director, RWM Consultancy
4.20
Closing remarks from the Chair
4.30
End of conference
Document Actions
 
  • © Informa 2008